A new study out of Tel Aviv University may help identify ways to improve the efficacy of lithium in patients who do not respond to the treatment, states an article in Medical Xpress. The study has identified the insulin-like growth factor 1 (IGF-1), which is known for its role in tissue growth, as being capable of increasing the lithium sensitivity of blood cells in bipolar disorder patients. This is important because the identification of insufficient IGF-1 activity may help to further identify drugs that are able to mimick its effects and, therefore, increase lithium sensitivity. To read this article in its entirety, click here.